KI
LCTX icon

Kapitalo Investimentos’s Lineage Cell Therapeutics LCTX Stock Holding History

Kapitalo Investimentos’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,130
Closed -$24.6K – 103
2025
Q2 		$24.6K Buy
+27,130
New +$16.1K 0.01% 117

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kapitalo Investimentos's LCTX Position: Q3 2025 in Review

Kapitalo Investimentos sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 27,130 shares — an estimated $24.6K sold.

Kapitalo Investimentos first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $24.6K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Kapitalo Investimentos reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Kapitalo Investimentos sold 27,130 Lineage Cell Therapeutics shares in Q3 2025, an estimated $24.6K.
  • Kapitalo Investimentos first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
  • Kapitalo Investimentos's Lineage Cell Therapeutics position peaked at $24.6K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Kapitalo Investimentos's 13F filing for Q3 2025, filed 3 Nov 2025.